A phase II study of combination therapy with irinotecan and S-1 (IRIS) in patients with advanced colorectal cancer

Cancer Chemotherapy and Pharmacology

Volumn 66, Issue 5, 2010, Pages 987-992

  Shiozawa, Manabu ^a   Akaike, Makoto ^a   Sugano, Nobuhiro ^a   Tsuchida, Kazuhito ^a   Yamamoto, Naoto ^a   Morinaga, Soichiro ^a  

^a KANAGAWA CANCER CENTER   (Japan)

Author keywords

Advanced colorectal cancer; Irinotecan; IRIS; S 1

Indexed keywords

5 CHLORO 2,4 DIHYDROXYPYRIDINE PLUS OXONATE POTASSIUM PLUS TEGAFUR; ANTINEOPLASTIC AGENT; FLUOROPYRIMIDINE DERIVATIVE; FLUOROURACIL; FOLINIC ACID; IRINOTECAN;

ABDOMINAL PAIN; ADULT; ADVANCED CANCER; AGED; ALOPECIA; ANEMIA; ANOREXIA; ARTICLE; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; COLORECTAL CANCER; COLORECTAL SURGERY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; FEMALE; HAND FOOT SYNDROME; HUMAN; LEUKOPENIA; MALE; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; OPEN STUDY; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; STOMATITIS; THROMBOCYTOPENIA; VOMITING;

ADMINISTRATION, ORAL; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BODY SURFACE AREA; CAMPTOTHECIN; COLORECTAL NEOPLASMS; DISEASE-FREE SURVIVAL; DRUG COMBINATIONS; FEMALE; FOLLOW-UP STUDIES; HUMANS; INFUSIONS, INTRAVENOUS; MALE; MIDDLE AGED; OXONIC ACID; SURVIVAL; TEGAFUR; TREATMENT OUTCOME;

EID: 77956230172     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-010-1278-0     Document Type: Article

References (24)

1. ML Rothenberg NJ Meropol EA Poplin E Van Cutsem S Wadler 2001 Mortality associated with irinotecan plus bolus fluorouracil/leucovorin: summary findings of an independent panel J Clin Oncol 19 3801 3807 1:CAS:528:DC%2BD3MXnsVKqsb0%3D 11559717
2. DJ Sargent D Niedzwiecki MJ O'Connell RL Schilsky 2001 Recommendation for caution with irinotecan, fluorouracil, and leucovorin for colorectal cancer N Engl J Med 345 144 145 10.1056/NEJMoa010957 1:STN:280:DC%2BD3MzpvVKnsg%3D%3D 11450666
3. Meta-analysis Group in Cancer 1998 Efficacy of intravenous continuous infusion of fluorouracil compared with bolus administration in advanced colorectal cancer J Clin Oncol 16 301 308
4. A De Gramont JF Bosset C Milan P Rougier O Bouche PL Etienne F Morvan C Louvet T Guillot E Francois L Bedenne 1997 Randomized trial comparing monthly low-dose leucovorin and fluorouracil bolus with bimonthly high-dose leucovorin and fluorouracil bolus plus continuous infusion for advanced colorectal cancer: a French intergroup study J Clin Oncol 15 808 815 9053508
5. JY Douillard D Cunningham AD Roth M Navarro RD James P Karasek P Jandik T Iveson J Carmichael M Alakl G Gruia L Awad P Rougier 2000 Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomized trial Lancet 355 1041 1047 10.1016/S0140-6736(00)02034-1 1:CAS:528:DC%2BD3cXisFOnsb4%3D 10744089
6. CJA Punt 2004 New options and old dilemmas in the treatment of patients with advanced colorectal cancer Ann Oncol 15 1453 1459 10.1093/annonc/mdh383 1:STN:280:DC%2BD2cvlvVGqsQ%3D%3D 15367403
7. C Tournigand T Andre E Achille G Lledo M Flesh D Mery-Mignard E Quinaux C Couteau M Buyse G Ganem B Landi P Colin C Louvet A De Gramont 2004 FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: A randomized GERCOR study J Clin Oncol 22 229 237 10.1200/JCO.2004.05.113 1:CAS:528:DC%2BD2cXpsVKit7w%3D 14657227
8. G Colucci V Gebbia G Paoletti F Giuliani M Caruso N Gebbia G Carteni B Agostara G Pezzella L Manzione N Borsellino A Misino S Romito E Durini S Cordio M Di Seri M Lopez E Maiello 2005 Phase III randomized trial of FOLFIRI versus FOLFOX4 in the treatment of advanced colorectal cancer: multicenter study of the Gruppo Oncologico Dell'italia Meridionale J Clin Oncol 23 4866 4875 10.1200/JCO.2005.07.113 1:CAS:528:DC%2BD2MXpsFWmt7s%3D 15939922
9. CH Kohne E Van Cutsem JWC Bokemeyer M El-Serafi MP Lutz M Lorenz P Reichardt H Ruckle-Lanz N Frickhofen R Fuchs HG Mergenthaler T Langenbuch U Vanhoefer P Rougier R Voigtmann L Muller B Genicot O Anak B Nordlinger 2005 Phase III study of weekly high-dose infusional fluorouracil plus folinic acid with or without irinotecan in patients with metastatic colorectal cancer: European Organisation for Research and Treatment of Cancer Gastrointestinal Group Study 40986 J Clin Oncol 23 4856 4865 10.1200/JCO.2005.05.546 15939923
10. M Verso G Agnelli 2003 Venous thromboembolism associated with long-term use of central venous catheters in cancer patients J Clin Oncol 21 3665 3675 10.1200/JCO.2003.08.008 14512399
11. DJ Kuter 2004 Thrombotic complication of central venous catheters in cancer patients Oncologist 9 207 216 10.1634/theoncologist.9-2-207 15047925
12. T Shirasaka K Nakano T Takechi H Satake J Uchida A Fujioka H Saito H Okabe K Oyama S Tateda N Unemi M Fukushima 1996 Antitumor activity of 1 M tegafur-0.4 M 5-chloro-2, 4-dihydroxy pyridine-1 M potassium oxonate (S-1) against human colon carcinoma orthotopically implanted into nude rats Cancer Res 56 2602 2606 1:CAS:528:DyaK28XjtlCgurg%3D 8653704
13. K Hirata N Horikoshi K Aiba M Okazaki R Denno K Sasaki Y Nakano H Ishizuka Y Yamada S Uno T Taguchi T Shirasaka 1999 Parmacokinetic study of S-1, a novel oral fluorouracil antitumor drug Clin Cancer Res 5 2000 2005 1:STN:280:DyaK1MvgtVSmtQ%3D%3D 10473078
14. M Shiozawa N Sugano K Tsuchida S Morinaga M Akaike Y Sugimasa 2009 A phase I study of combination therapy with S-1 and irinotecan (CPT-11) in patients with advanced colorectal cancer J Cancer Res Clin Oncol 135 365 370 10.1007/s00432-008-0480-5 1:CAS:528:DC%2BD1MXht1Ogtbo%3D 18974999
15. P Therasse SG Arbuck EA Eisenhauer J Wanders RS Kaplan L Rubinstein J Verweij M Van Glabbeke AT van Oosterom MC Christian SG Gwyther 2000 New guidelines to evaluate the response to treatment in solid tumors J Natl Cancer Inst 92 205 216 10.1093/jnci/92.3.205 1:STN:280:DC%2BD3c7it1Gitg%3D%3D 10655437
16. A Goto Y Yamada H Yasui K Kato T Hamaguchi K Muro Y Shimada K Shirao 2006 Phase II study of combination therapy with S-1 and irinotecan in patients with advanced colorectal cancer Ann Oncol 17 968 973 10.1093/annonc/mdl066 1:STN:280:DC%2BD283nslenug%3D%3D 16603600
17. A Tsunoda N Yasuda K Nakao K Narita M Watanabe N Matsui M Kusano 2009 Phase II study of S-1 combined with irinotecan (CPT-11) in patients with advanced colorectal cancer Oncology 77 192 196 10.1159/000236017 1:CAS:528:DC%2BD1MXhtFOhtrvM 19729976
18. Yuki S, Komatsu Y, Sogabe S, Iwanaga I, Kudo M, Miyagishima T, Nakamura M, Hatanaka K, Asaka M, Sakata Y (2009) Phase II study of combination with irinotecan and S-1(IRIS) for inoperable recurrent advanced colorectal cancer (HGCSG0302): Final analysis. Gastrointestinal Cancer Symposium. (Abstract No. 463)
19. HJ Mackay M Hill C Twelves R Glasspool T Price S Campbell A Massey MA Macham M Uzzel SM Bailey C Martin D Cunningham 2003 A phase I/II study of oral uracil/tegafur (UFT), leucovorin and irinotecan in patients with advanced colorectal cancer Ann Oncol 14 1264 1269 10.1093/annonc/mdg340 1:STN:280:DC%2BD3szkvVaqtw%3D%3D 12881390
20. E Bajetta M Di Bartolomeo L Mariani A Cassata S Artale S Frustaci G Pinotti A Bonetti I Carreca G Biasco L Bonaglia G Marini A Iannelli D Cortinovis E Ferrario E Baretta A Lambiase R Buzzoni 2004 Randomized multicenter phase II trial of two defferent schedules of irinotecan combined with capecitabine as first-line treatment in metastatic colorectal carcinoma Cancer 100 279 287 10.1002/cncr.11910 1:CAS:528:DC%2BD2cXhtVOhu7Y%3D 14716761
21. Grothey A, Jordan K, Kellner O, Constantin C, Dietrich G, Kroening H, Mantovani L, Schlichting C, Forstbauer H, Schmoll HJ (2004) Capecitabine/ irinotecan (CapIri) and capecitabine/oxaliplatin (CapOx) are active second-line protocols in patients with advanced colorectral cancer(ACRC) after failure of first-line combination therapy: results of a randomized phase II study. J Clin Oncol 22:No14S. (abstract3534)
22. MM Borner J Bernhard D Dietrich R Popescu M Wernli P Saletti D Rauch R Herrmann D Koeberle H Honegger P Brauchli D Lanz AD Roth 2005 A randomized phase II trial of capecitabine and two different schedules of irinotecan in first-line treatment of metastatic colorectal cancer:efficacy, quality-of-life and toxicity Ann Oncol 16 282 288 10.1093/annonc/mdi047 1:STN:280: DC%2BD2M%2FjvFyhsA%3D%3D 15668285
23. YZ Patt FC Lee JE Leibmann D Diamandidis SG Eckhardt M Javle GR Justice W Keiser JR Salvatore A Bexon E Lin 2007 Capecitabine plus 3-weekly irinotecan (XELIRI regimen) as first-line chemotherapy for metastatic colorectal cancer: phase II trial results Am J Clin Oncol 30 350 357 10.1097/COC.0b013e31804b40bb 1:CAS:528:DC%2BD2sXhtVeiu7bN 17762434
24. E Bajetta M Di Bartolomeo R Buzzoni L Mariani N Zilembo E Ferrario S Lo Vullo E Aitini L Isa C Barone S Jacobelli E Recaldin G Pinotti A Iop 2007 Uracil/ftorafur/leucovorin combined with irinotecan (TEGAFIRI) or oxaliplatin (TEGAFOX) as first-line treatment for metastatic colorectal cancer patients: results of randomized phase II study Br J Cancer 96 439 444 10.1038/sj.bjc. 6603493 1:CAS:528:DC%2BD2sXhtlKjtrs%3D 17245343